- ¥158bn
- ¥108bn
- ¥97bn
Table: Kissei Pharm -2020/21 group results
Table: Kissei Pharm -2020/21 parent results
Table: Kissei Pharm -2020/21 group forecast
Table: Kissei Pharm - 9-MTH group results
Table: Kissei Pharm - 6-MTH group results
2020 6-month group forecast
Table: Kissei Pharm -Q1 group results
Table: Kissei Pharm -2019/20 parent results
Table: Kissei Pharm -2019/20 group results
Table: Kissei Pharm - 9-MTH group results
Table: Kissei Pharm - 6-MTH group results
Brief: Rigel's Fostamatinib Enters Phase 3 Clinical Trial In Japan With Kissei Pharmaceuticals For The Treatment Of Chronic Immune Thrombocytopenia
Table: Kissei Pharm -Q1 group results
Table: Kissei Pharm -2018/19 group results
Table: Kissei Pharm -2018/19 parent results
Table: Kissei Pharm - 9-MTH group results
Table: Kissei Pharm - 6-MTH group results
Brief: Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder
Table: Kissei Pharm -Q1 group results